Research Article

Effects of vitamin D on proliferation, invasion and energy metabolism of MCF-7 breast cancer cell line

Volume: 52 Number: 3 December 30, 2022
EN

Effects of vitamin D on proliferation, invasion and energy metabolism of MCF-7 breast cancer cell line

Abstract

Background and Aims: 1,25(OH)2D3 (vitamin D) is a pleiotropic hormone with anti-proliferative, pro-apoptotic, and pro- differentiation effects on various cell types, which suggest anti-cancer activity in addition to its classical regulatory action on calcium and phosphate metabolism.
Methods: We aimed to put forward the effects of vitamin D in various concentrations and time intervals on cell proliferation and invasion of human estrogen receptor-positive breast cancer (MCF-7) cells by real-time cell electronic sensing system (xCELLigence). A determined dose of the IC50 was applied on samples taken from cell lysates and analyzed the levels of the energy. We also aimed to clarify how vitamin D effects the activity of the protease uPA and their relations with each other.
Results: Vitamin D showed a cytotoxic effect on MCF-7 cells in a time and dose dependent manner, with dose of IC50 found to be 140 nM. ATP, ADP, and AMP levels, as well as uPA activities were respectively increased in vitamin D treatment group compared to the control group for the first 24 hours while decreasing at 48, 72, and 96 hours. We determined that 70 and 140 nM vitamin D were decreased in invasion of MCF-7 cells compared to control cells.
Conclusion: We observed that proliferation and invasion of breast cancer cells were inhibited by vitamin D treatment on a dose and time dependent manner, and also vitamin D supplementation decreased uPA activity and energy levels. Further studies on the mechanisms of vitamin D and the formulation of none-hypercalcemic analogues in featured are needed.

Keywords

Supporting Institution

Selcuk University Scientific Research Project

Project Number

11202002

References

  1. Abbas, S., Chang‐Claude, J., & Linseisen, J. (2009). Plasma 25‐hy- droxyvitamin D and premenopausal breast cancer risk in a Ger- man case‐control study. International journal of cancer, 124(1), 250-255.
  2. Anderson, P. H. (2017). Vitamin D Activity and Metabolism in Bone. Current Osteoporosis Reports, 15(5), 443-449. doi:10.1007/ s11914-017-0394-8
  3. Brosseau, C., Pirianov, G., & Colston, K. (2010). Involvement of stress activated protein kinases (JNK and p38) in 1, 25 dihydroxyvitamin D3-induced breast cell death. Steroids, 75(13-14), 1082-1088.
  4. Chiang, K. C., Chen, S. C., Yeh, C. N., Pang, J. H., Shen, S. C., Hsu, J. T., Chen, T. C. (2014). MART-10, a less calcemic vitamin D analog, is more potent than 1alpha,25-dihydroxyvitamin D3 in inhibit- ing the metastatic potential of MCF-7 breast cancer cells in vitro. Journal of Steroid Biochemistry and Molecular Biology, 139, 54-60. doi:10.1016/j.jsbmb.2013.10.005
  5. Cimen, B., Turkozkan, N., Unlu, A., & Erbil, M. K. (2005). Effects of melatonin on 3-nitrotyrosine formation and energy charge ratio in guinea pig kidney in LPS-induced stress. Cell Biochemistry and Function, 23(4), 273-277. doi:10.1002/cbf.1151
  6. Diesing, D., Cordes, T., Fischer, D., Diedrich, K., & Friedrich, M. (2006). Vitamin D--metabolism in the human breast cancer cell line MCF-7. Anticancer Research, 26(4A), 2755-2759.
  7. Dinicola, S., Pasqualato, A., Cucina, A., Coluccia, P., Ferranti, F., Cani- pari, R., . . . Bizzarri, M. (2014). Grape seed extract suppresses MDA- MB231 breast cancer cell migration and invasion. European Jour- nal of Nutrition, 53(2), 421-431. doi:10.1007/s00394-013-0542-6
  8. Duffy, M. J., & Duggan, C. (2004). The urokinase plasminogen ac- tivator system: a rich source of tumour markers for the individu- alised management of patients with cancer. Clinical Biochemistry, 37(7), 541-548. doi:10.1016/j.clinbiochem.2004.05.013

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Research Article

Publication Date

December 30, 2022

Submission Date

June 21, 2022

Acceptance Date

November 28, 2022

Published in Issue

Year 2022 Volume: 52 Number: 3

APA
Korucu, E. N., & Unlu, A. (2022). Effects of vitamin D on proliferation, invasion and energy metabolism of MCF-7 breast cancer cell line. İstanbul Journal of Pharmacy, 52(3), 311-317. https://doi.org/10.26650/IstanbulJPharm.2022.1133531
AMA
1.Korucu EN, Unlu A. Effects of vitamin D on proliferation, invasion and energy metabolism of MCF-7 breast cancer cell line. iujp. 2022;52(3):311-317. doi:10.26650/IstanbulJPharm.2022.1133531
Chicago
Korucu, Emine Nedime, and Ali Unlu. 2022. “Effects of Vitamin D on Proliferation, Invasion and Energy Metabolism of MCF-7 Breast Cancer Cell Line”. İstanbul Journal of Pharmacy 52 (3): 311-17. https://doi.org/10.26650/IstanbulJPharm.2022.1133531.
EndNote
Korucu EN, Unlu A (December 1, 2022) Effects of vitamin D on proliferation, invasion and energy metabolism of MCF-7 breast cancer cell line. İstanbul Journal of Pharmacy 52 3 311–317.
IEEE
[1]E. N. Korucu and A. Unlu, “Effects of vitamin D on proliferation, invasion and energy metabolism of MCF-7 breast cancer cell line”, iujp, vol. 52, no. 3, pp. 311–317, Dec. 2022, doi: 10.26650/IstanbulJPharm.2022.1133531.
ISNAD
Korucu, Emine Nedime - Unlu, Ali. “Effects of Vitamin D on Proliferation, Invasion and Energy Metabolism of MCF-7 Breast Cancer Cell Line”. İstanbul Journal of Pharmacy 52/3 (December 1, 2022): 311-317. https://doi.org/10.26650/IstanbulJPharm.2022.1133531.
JAMA
1.Korucu EN, Unlu A. Effects of vitamin D on proliferation, invasion and energy metabolism of MCF-7 breast cancer cell line. iujp. 2022;52:311–317.
MLA
Korucu, Emine Nedime, and Ali Unlu. “Effects of Vitamin D on Proliferation, Invasion and Energy Metabolism of MCF-7 Breast Cancer Cell Line”. İstanbul Journal of Pharmacy, vol. 52, no. 3, Dec. 2022, pp. 311-7, doi:10.26650/IstanbulJPharm.2022.1133531.
Vancouver
1.Emine Nedime Korucu, Ali Unlu. Effects of vitamin D on proliferation, invasion and energy metabolism of MCF-7 breast cancer cell line. iujp. 2022 Dec. 1;52(3):311-7. doi:10.26650/IstanbulJPharm.2022.1133531